BioNexus Gene Lab enters strategic alliance for VitaGuard MRD platform in SE Asia

BioNexus Gene Lab Corp

BGLC to acquire equity stake in Fidelion Diagnostics and exclusive commercial rights to VitaGuard MRD platform across ASEAN.
VitaGuard is tumour-naïve ctDNA test with 0.02% VAF sensitivity, 95% cfDNA recovery; cost <$300 vs >$3,000 legacy assays.
Southeast Asia cancer incidence projected at 2.4M new cases annually by 2030, creating multi-billion-dollar recurring market.
Cross-shareholdings and license fee align both companies; rollout begins in Singapore and Malaysia.
Partnership includes joint development of companion diagnostics and AI-powered Cancer Interception System.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.